FDA Greenlights Gene Therapy, Because Patience Isn’t a Drug
In a plot twist worthy of a soap opera, the FDA announced it’s 'clearing the way' for Sarepta Therapeutics to resume shipments of their gene therapy for Duchenne muscular dystrophy to some patients. Yes, just some, because apparently miracles come with fine print. The FDA’s official line? They’re 'clearing the way,' which sounds a bit like popping open a space in traffic, except this lane could save lives. Gene therapy shipments resumed, but if you were hoping for a full-on party, well, it’s more of a dignified nod: progress served with a side of bureaucratic seasoning.
Share the Story
FDA finally said 'go' for gene therapy shipments, or as they put it, 'clearing the way.' Someone tell my delivery app to work on that kind of speed. #MiracleMiles
Oh look, FDA is 'clearing the way' for some shipments like it's GPS rerouting around traffic jams. Your gene therapy might arrive sometime between now and the heat death of the universe.
Resuming gene therapy shipments to some patients is like giving only half your friends passes to the Electric Daisy Carnival—exclusive, selective, and sure to cause FOMO.
Source: Statnews | Published: 7/28/2025 | Author: Adam Feuerstein
More Articles in Health
Politico Announces Australia Launch for 2026, Because Why Not Start Late?
Trump Promises Retirement Plan That Matches Generosity of Federal Workers’ Excuses
Trump Calls Supreme Court 'Unfortunate,' Then Hits Economy with ‘Better’ 10% Global Tariff
Mom Skips Junior Year Exams, Swaps Algebra for Penguins in Antarctica
America Solves Fentanyl Crisis by Inventing Pink Cocaine Zombie Apocalypse
French Obesity Rate Mystifies US After Cheese, Wine, Bread Diet Approved
Woman Waited Years to Wear Favorite Clothes; Life Finally Happened, Clothes Revolted
RFK Jr. Promises To Investigate Ultra-Processed Junk Food but Won't Regulate It
